Transaction Information
Harrow Health, Inc. (NASDAQ: HROW) priced an underwritten registered public offering of 3,380,282 shares of its common stock at the public offering price of $17.75 per share. The aggregate gross proceeds to Harrow, before deducting underwriting discounts and commissions and offering expenses, were $60.0 million. Harrow has granted the underwriters a 30-day option to purchase an additional 507,042 shares of its common stock in connection with the offering.
Ladenburg Thalmann & Co. Inc. acted as co-manager in connection with this offering.
About Harrow Health, Inc.
Harrow Health, Inc. (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. For more information on Harrow visit https://www.harrow.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.